Image: AI-generated editorial illustration
Czech medtech startup Kardi Ai has raised a €5.3 million Series A led by German health-tech venture fund Callisto Health, the company said on November 11, 2026. The round also included Česká spořitelna and Slovenská sporiteľňa through Seed Starter, along with BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels.
Czech medtech startup Kardi Ai has raised a €5.3 million Series A led by German health-tech venture fund Callisto Health, with participation from Česká spořitelna and Slovenská sporiteľňa through Seed Starter, BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels. The company said the capital will support expansion across Europe and Asia, with Germany the immediate priority and planned entries into India, the UAE and Singapore.
Kardi Ai builds a long-term heart-monitoring platform that combines a chest strap with an ECG sensor, a mobile application and AI-based analysis of ECG recordings. The system is designed to support clinical decision-making rather than provide diagnoses, and the company is developing predictive models intended to estimate arrhythmia risk before it occurs. Tech.eu reported that those models still require clinical validation and regulatory approval before they can be used in medical practice.
What does Kardi Ai's product do?
Kardi Ai's product is meant to extend rhythm monitoring beyond a short clinic visit. The company uses a chest strap with a built-in ECG sensor, connected to a mobile app where AI analyzes the recordings. The Recursive reported that users can see the results themselves and share them with a doctor when needed, and that longer-term monitoring can help capture intermittent arrhythmias that may be missed in short clinic check-ups.
Tech.eu described the platform as a system that supports clinical decision-making, not a standalone diagnostic tool.
Who backed the Series A?
Callisto Health led the round, according to Tech.eu and The Recursive. The backers also included Česká spořitelna and Slovenská sporiteľňa through Seed Starter, as well as BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels.
The Recursive quoted Callisto Health's Stefan Eckhardt saying Kardi Ai had already built a certified medical product used in real-world settings in Central and Eastern Europe. Seed Starter CEO Tomáš Milota said Česká spořitelna has offered Kardi Ai to its own employees as a benefit since 2024, and that the bank invested after validating the solution internally and after Kardi Ai achieved MDR certification. The Recursive also reported that for Slovenská sporiteľňa's Seed Starter, Kardi Ai is its first healthtech investment.
BrightCap Ventures' Georgi Mitov said BrightCap had also led Kardi Ai's pre-seed round in 2022. According to the company, this is the largest round a Czech medtech startup has raised to date. The Recursive reported that Kardi Ai was valued at €23 million after the Series A.
Where is Kardi Ai already operating?
Kardi Ai already works with more than 70 hospitals and over 20 corporate and employee-benefit partners in the Czech Republic, and Tech.eu attributed to the company that its technology is used by more than 6,000 people there. Tech.eu also attributed to the company that its monitoring system has identified possible cardiac arrhythmias in about one quarter of users, including more than 500 critical findings.
The company expanded into Slovakia several months before the report and said it works with more than 20 physicians there, mainly cardiologists. The Recursive also said Kardi Ai sells through its own e-shop, Alza and the online pharmacy Moja Lekáreň, in addition to hospitals and clinics. In terms of geography, the company already operates in Czechia, Slovakia, Poland, Romania and Bulgaria.
What happens after the round?
Kardi Ai said the financing will be used to enter new markets in Europe and Asia and to develop models that estimate arrhythmia risk. Tech.eu said the Series A proceeds will support expansion across Europe and Asia, with Germany as an immediate priority and planned entries into India, the UAE and Singapore.
The Recursive reported that Kardi Ai has completed pilot projects in Germany and is preparing to launch there. In India, The Recursive reported that Kardi Ai received an MD-15 import licence from India's CDSCO in July 2026 covering both hardware and software, and planned to start in Hyderabad in the last quarter of 2026. The company also holds a Medical Device Registration Certificate from the UAE Ministry of Health and Prevention, and is finishing medical-device approval in Singapore, which it plans to use as an entry point into Southeast Asia.
The Recursive said Kardi Ai's next Southeast Asian targets include the Philippines, Indonesia and Vietnam. CEO Vlastimil Hrabal said the new capital will be used to validate the technology at global scale across patient demographics and pursue Kardi Ai's ambition to become a leading provider of long-term ECG monitoring in its target markets. He also said Kardi Ai is moving from detecting rhythm disorders toward technology that can identify elevated risk before arrhythmia appears. The company was founded in Olomouc in 2022 by cardiologist Prof. Tomáš Skála, entrepreneur Stephen Burke, technologist Pavel Digaňa and product designer David Skála, with Hrabal later joining as CEO.
Sources
- Czech medtech Kardi Ai raises €5.3M to advance predictive heart monitoringtech.eu· Tech.eu
- Czech medtech Kardi Ai raises €5.3M to advance predictive heart monitoringtech.eu· Tech.eu
- Kardi Ai Raises €5.3M Series A Led by Callisto Healththerecursive.com· The Recursive
- Kardi Ai Raises $6.0M for Heart Monitoring Techtrysignalbase.com· Signalbase
- Kardi Ai €1.1M Seed Funding (2025) | Investors & Contactsfundup.ai· FundUpUnverified URL



